Javelin's Dyloject patent extended 10 years

Massachusetts, USA-based Javelin Pharmaceuticals, a developer of novel products for pain control, has been awarded a new European patent covering 30 European countries, including European Union major market countries. This new patent significantly broadens and extends Javelin's patent protection for Dyloject (diclofenac, injectable), its lead drug candidate. European Patent No 1 574 221 entitled Stable Injectable Compositions, extends the product's patent life and exclusivity from 2014 into 2024. A corresponding patent application is pending in the USA.

"Issuance of this key European patent represents a significant increase in value for our European Dyloject franchise," said, David Bernstein, the firm's general counsel. "Extension of exclusivity into 2024 provides substantially greater economic potential, adding 10 years of commercial opportunity for Dyloject. This is very good news as we anticipate approval and are preparing for commercial launch of Dyloject in the UK," he added.